Craig-Hallum raised the firm’s price target on Koru Medical (KRMD) to $6.25 from $6 and keeps a Buy rating on the shares following Koru’s strong quarter, as international growth continues to inflect and the core U.S. SCIg business delivers above-market performance. Overall, revenue grew 27% year-over-year, surpassing expectations, and guidance was raised.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRMD: